Ma Ka Wing, Cheung Tan To
Department of Surgery, Queen Mary Hospital, the University of Hong Kong, Hong Kong.
Hepat Oncol. 2017 Jan;4(1):15-24. doi: 10.2217/hep-2016-0010. Epub 2017 Jul 6.
Orthotopic liver transplantation (LT) has been regarded as the best cure among the three curative treatment modalities. However, when to consider LT in hepatocellular carcinoma (HCC) patients remains a complicated clinical question. In this article, we will look into the recent updates in the context of LT for HCC, including the timing of orthotopic LT (primary or salvage LT), patient selection criteria, newer prognostic markers and scoring systems, down-staging and bridging therapy, salvage LT and treatment option of post-LT HCC recurrence. Evolution of immunosuppressive therapy and future development of the LT for HCC will also be discussed.
原位肝移植（LT）被认为是三种根治性治疗方式中最佳的治疗方法。然而，对于肝细胞癌（HCC）患者何时考虑进行肝移植仍是一个复杂的临床问题。在本文中，我们将探讨肝癌肝移植方面的最新进展，包括原位肝移植的时机（初次或挽救性肝移植）、患者选择标准、新的预后标志物和评分系统、降期和桥接治疗、挽救性肝移植以及肝移植后肝癌复发的治疗选择。还将讨论免疫抑制治疗的进展以及肝癌肝移植的未来发展。
